Rentokil jumps as US business shows first improvements

Rentokil Initial shares jumped 10% after the company reported H1 2025 revenues up 3.1% to $3.36 billion and reaffirmed its full-year outlook, primarily driven by encouraging momentum in its North American business. Despite an 8.7% decline in adjusted profit before tax to $418 million and margin compression to 15.2%, North American organic growth improved to 1.4% in Q2 from 0.7% in Q1, with early signs of residential and termite lead flow growth. Strong free cash flow conversion of 93% further bolstered investor confidence in the reaffirmed full-year guidance.

Analysis

Rentokil Initial's (RTO) first-half 2025 results triggered a 10% share price increase, driven not by historical profitability but by forward-looking operational indicators. While adjusted profit before tax fell 8.7% to $418 million and margins contracted 120 basis points, investors focused on the reaffirmed full-year outlook and nascent signs of a turnaround in the critical North American market. Revenue grew 3.1% to $3.36 billion, supported by an acceleration in North American organic growth from 0.7% in Q1 to 1.4% in Q2. This momentum is further substantiated by management's comment that residential and termite lead flow grew 6.6% in June, the first positive reading for the year. The company's financial position was also bolstered by exceptionally strong free cash flow conversion of 93%, well ahead of its 80% guidance, and the decision to maintain its interim dividend, signaling confidence in meeting full-year market expectations.

Key Decisions for Investors

• Given the reaffirmed guidance and early signs of a turnaround in the critical North American market, investors could view the current momentum as a positive signal, despite the decline in H1 profitability.
• Investors should closely monitor the next quarter's results to confirm if the 6.6% growth in June's lead flow translates into sustained revenue acceleration and organic growth in North America, as this is the core pillar of the current investment thesis.
• The significant margin compression of 120 basis points remains a key risk, and investors should scrutinize future earnings for evidence of margin stabilization or recovery alongside the expected revenue growth.